JP2024525222A - Erk1/2阻害剤併用療法 - Google Patents

Erk1/2阻害剤併用療法 Download PDF

Info

Publication number
JP2024525222A
JP2024525222A JP2023579857A JP2023579857A JP2024525222A JP 2024525222 A JP2024525222 A JP 2024525222A JP 2023579857 A JP2023579857 A JP 2023579857A JP 2023579857 A JP2023579857 A JP 2023579857A JP 2024525222 A JP2024525222 A JP 2024525222A
Authority
JP
Japan
Prior art keywords
cancer
compound
administered
pharma
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525222A5 (cg-RX-API-DMAC7.html
Inventor
グプタ,サンディープ
デニス,ルイス
レディ,サンジーバ
コーコラン,ライアン,ビー.
Original Assignee
アサナ バイオサイエンシーズ,エルエルシー
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アサナ バイオサイエンシーズ,エルエルシー, ザ ジェネラル ホスピタル コーポレイション filed Critical アサナ バイオサイエンシーズ,エルエルシー
Publication of JP2024525222A publication Critical patent/JP2024525222A/ja
Publication of JP2024525222A5 publication Critical patent/JP2024525222A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023579857A 2021-06-24 2022-06-23 Erk1/2阻害剤併用療法 Pending JP2024525222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214764P 2021-06-24 2021-06-24
US63/214,764 2021-06-24
PCT/US2022/034702 WO2022271935A1 (en) 2021-06-24 2022-06-23 Erk1/2 inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2024525222A true JP2024525222A (ja) 2024-07-10
JP2024525222A5 JP2024525222A5 (cg-RX-API-DMAC7.html) 2025-06-24

Family

ID=84544892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579857A Pending JP2024525222A (ja) 2021-06-24 2022-06-23 Erk1/2阻害剤併用療法

Country Status (8)

Country Link
US (1) US20240316046A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358967A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525222A (cg-RX-API-DMAC7.html)
KR (1) KR20240055721A (cg-RX-API-DMAC7.html)
CN (1) CN117957001A (cg-RX-API-DMAC7.html)
AU (1) AU2022300355A1 (cg-RX-API-DMAC7.html)
CA (1) CA3223692A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022271935A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019186488A1 (en) * 2018-03-30 2019-10-03 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
WO2020231976A1 (en) * 2019-05-16 2020-11-19 Eli Lilly And Company Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer
WO2021086726A1 (en) * 2019-10-28 2021-05-06 Asan BioSciences, LLC Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127282A1 (en) * 2016-01-19 2017-07-27 The General Hospital Corporation Cancer treatments and methods of selecting same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019186488A1 (en) * 2018-03-30 2019-10-03 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
WO2020231976A1 (en) * 2019-05-16 2020-11-19 Eli Lilly And Company Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer
WO2021086726A1 (en) * 2019-10-28 2021-05-06 Asan BioSciences, LLC Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER DISCOV., vol. 8(4), JPN6026019656, 2018, pages 417 - 427, ISSN: 0005860772 *
MOLECULAR CARCINOGENESIS, vol. 60, JPN6026019657, January 2021 (2021-01-01), pages 201 - 212, ISSN: 0005860773 *

Also Published As

Publication number Publication date
CN117957001A (zh) 2024-04-30
CA3223692A1 (en) 2022-12-29
US20240316046A1 (en) 2024-09-26
KR20240055721A (ko) 2024-04-29
EP4358967A4 (en) 2025-06-25
WO2022271935A1 (en) 2022-12-29
EP4358967A1 (en) 2024-05-01
AU2022300355A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
US20240285625A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
US20240207269A1 (en) Uses of heterocyclic inhibitors of erk1/2
AU2014233805B2 (en) Combination therapy comprising a B-Raf inhibitor and a second inhibitor
US20240316046A1 (en) Erk1/2 inhibitor combination therapy
US20250120978A1 (en) Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy
JP5890310B2 (ja) 組合せ
US20240307392A1 (en) Erk1/2 and egfr inhibitors combination therapy
CN117858725A (zh) Erk1/2和egfr抑制剂组合疗法
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
CN117897158A (zh) Erk1/2和shp2抑制剂组合疗法
WO2026107237A1 (en) Ras and egfr inhibitors combination therapy
WO2026107242A1 (en) Ras and pd-1 or pd-l1 inhibitors combination therapy
WO2026107317A1 (en) Ras inhibitors combination therapy
EA040191B1 (ru) Комбинированная терапия
HK1214135B (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260518

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260521